Crispr gene editing concept

The CRISPR-Cas9 gene editing technique revolutionizes molecular biology by enabling precise DNA modifications in living organisms.

About this subject

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing technology based on a bacterial defense system. Discovered by Francisco Mojica in the 1990s and adapted by Jennifer Doudna and Emmanuelle Charpentier in 2012, CRISPR-Cas9 won the Nobel Prize in Chemistry in 2020. Unlike previous methods such as ZFNs and TALENs, CRISPR is simpler, cheaper, and more efficient, allowing precise DNA cuts using a guide RNA.

Applications range widely: in agriculture for pest-resistant crops, in medicine for treating genetic diseases like sickle cell anemia and beta-thalassemia, and in basic research for studying gene functions. Clinical trials are underway to edit human cells in vivo, for instance to combat cancer or muscular dystrophy. However, editing germline cells (heritable changes) raises significant ethical concerns.

Notably, the name "CRISPR" comes from a repetitive DNA pattern in bacteria. The original system was observed in Escherichia coli. Currently, variants like CRISPR-Cas9, Cas12, and Cas13 offer different capabilities such as base editing and prime editing, increasing precision. Countries including Brazil are also investing in research, with groups like the Brazilian National Biosciences Laboratory (LNBio) developing therapies.

Frequently Asked Questions

How does CRISPR-Cas9 work?

The system uses a Cas9 protein guided by a synthetic RNA to cut DNA at a specific location, allowing gene insertion, deletion, or modification.

What are the main medical applications of CRISPR?

It is used to treat genetic diseases like sickle cell anemia, and in cancer research, editing T cells for immunotherapy, and correcting mutations in vitro.

Are there ethical risks in using CRISPR?

Yes, especially in germline editing, which can be heritable, raising concerns about eugenics and unforeseen genome effects.